Hepatitis B Virus (HBV) Capsid Inhibitors Market Report 2026

The hepatitis b virus (hbv) capsid inhibitors market size has grown rapidly in recent years. It will grow from $0.52 billion in 2025 to $0.59 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to global burden of chronic hepatitis b infection, limitations of existing antiviral therapies, early clinical validation of capsid inhibitors, increased virology research funding, growing pharmaceutical pipeline activity.

The hepatitis b virus (hbv) capsid inhibitors market size is expected to see rapid growth in the next few years. It will grow to $0.98 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to expansion of combination regimens with immunotherapies, rising investment in curative hbv treatments, increasing regulatory approvals for novel antivirals, growing global screening programs, advancement of next-generation capsid inhibitors. Major trends in the forecast period include increasing focus on functional cure strategies for hbv, rising development of capsid assembly modulators, growing combination therapy approaches, expansion of late-stage clinical pipelines, enhanced targeting of viral replication pathways.

The rising incidence of hepatitis B virus infections is anticipated to drive expansion in the hepatitis B virus (HBV) capsid inhibitors market. Hepatitis B virus (HBV) infections are liver conditions triggered by the hepatitis B virus, which can cause acute and chronic illnesses; they spread via contact with infected blood or bodily fluids, potentially leading to severe issues like liver cirrhosis or cancer. The growing prevalence of HBV infections stems primarily from insufficient vaccination rates, leaving significant segments of the population vulnerable and facilitating easier transmission through exposure to contaminated blood or fluids. Hepatitis B virus (HBV) capsid inhibitors combat these infections by interfering with viral capsid formation and assembly, which halts replication and curbs the virus's spread inside the body. For instance, in April 2024, a World Health Organization (WHO) report from the Switzerland-based intergovernmental body revealed that, as of late 2022, just 13% of people with chronic hepatitis B had received a diagnosis, while roughly 3% (7 million) were on antiviral treatment. For hepatitis C, 36% had been diagnosed, with 20% (12.5 million) accessing curative therapy - numbers well short of the 2030 global goal to treat 80% of those with chronic hepatitis B and C. Thus, the surge in hepatitis B virus infections is fueling demand for the hepatitis B virus (HBV) capsid inhibitors market.

Major companies in the hepatitis B virus (HBV) capsid inhibitors market are prioritizing innovations like oral small-molecule capsid assembly modulators to boost antiviral effectiveness, enhance patient adherence, and deliver long-term viral control. Oral small-molecule capsid assembly modulators are orally delivered antiviral drugs that disrupt the formation of the HBV capsid, preventing replication and lowering viral levels in the body. For example, in July 2024, Aligos Therapeutics, Inc., a U.S.-based clinical-stage biopharmaceutical firm, partnered with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to initiate a clinical trial assessing novel therapies for chronic hepatitis B (CHB), utilizing its cutting-edge capsid assembly modulator technology to improve antiviral performance and speed up next-generation HBV treatment development. This initiative represents a key milestone in Aligos’s efforts to create potent and possibly curative options for chronic hepatitis B patients.

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, collaborated with Assembly Biosciences Inc. to combine its antiviral expertise with Assembly Biosciences Inc.’s advanced capsid inhibitor technology, speeding up the creation of next-generation small-molecule antivirals. These antivirals aim to boost viral suppression, enhance treatment results, and possibly deliver a functional cure for individuals with chronic hepatitis B infection. Assembly Biosciences Inc. is a US-based biotechnology company focused on discovering and developing antiviral therapeutics, including innovative agents against the hepatitis B virus (HBV) and other viral infections.

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis b virus (hbv) capsid inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hbv capsid inhibitors market by increasing costs of imported active pharmaceutical ingredients, specialized chemical intermediates, biologic reagents, and clinical trial supplies. North America and Europe are most affected due to reliance on imported high-value drug substances and research materials, while Asia-Pacific faces cost pressure on manufacturing scale-up and export-oriented production. These tariffs are increasing development expenses and extending commercialization timelines. However, they are also encouraging regional manufacturing investments, localized clinical supply chains, and strategic collaborations to strengthen domestic antiviral drug production.

The hepatitis b virus (hbv) capsid inhibitors market research report is one of a series of new reports that provides hepatitis b virus (hbv) capsid inhibitors market statistics, including hepatitis b virus (hbv) capsid inhibitors industry global market size, regional shares, competitors with a hepatitis b virus (hbv) capsid inhibitors market share, detailed hepatitis b virus (hbv) capsid inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis b virus (hbv) capsid inhibitors industry. This hepatitis b virus (hbv) capsid inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatitis B virus (HBV) capsid inhibitors are a class of antiviral drugs that disrupt the assembly, disassembly, or stability of the viral capsid, crucial for HBV replication. They target the core protein that forms the protective shell around the viral DNA, blocking the creation of new infectious particles. Through interference with capsid formation, these inhibitors lower viral load and slow disease progression. HBV capsid inhibitors offer a promising strategy for reaching a functional cure in chronic hepatitis B.

The primary categories of drugs for hepatitis B virus (HBV) capsid inhibitors consist of core protein allosteric modulators (CpAMs), capsid assembly modulators, and additional types. HBV capsid inhibitors, alternatively referred to as core protein allosteric modulators (CpAMs), function as antiviral compounds that interfere with the formation or stability of the viral capsid, thus preventing HBV replication and lowering viral levels. Relevant applications encompass chronic hepatitis B, acute hepatitis B, and further uses, with distribution occurring via hospital pharmacies, retail pharmacies, online pharmacies, and other channels. End users comprise hospitals, clinics, research institutes, and others.

The hepatitis B virus (HBV) capsid inhibitors market consists of sales of vebicorvir, bepirovirsen, cavrotolimod, hepcludex, and morphothiadin. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.